Related Experiment Video
Updated: Jun 14, 2026
08:49
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
B-type natriuretic peptide-guided heart failure therapy: A meta-analysis
Pramote Porapakkham1, Pornwalee Porapakkham, Hendrik Zimmet
1Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia.
Archives of Internal Medicine
|March 24, 2010
Summary
B-type natriuretic peptide (BNP)-guided therapy significantly lowers mortality in chronic heart failure (HF) patients, particularly those under 75. This approach may increase the use of life-saving HF medications, though hospitalization rates remain unchanged.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Trials
Background:
- Plasma B-type natriuretic peptide (BNP) levels are utilized in managing chronic heart failure (HF).
- Previous randomized controlled trials (RCTs) have yielded uncertain benefits regarding BNP-guided treatment.
- A meta-analysis was conducted to clarify the impact of BNP-guided therapy on cardiovascular outcomes in chronic HF patients.
Purpose of the Study:
- To evaluate the overall effect of B-type natriuretic peptide (BNP)-guided drug therapy on cardiovascular outcomes.
- To determine if BNP-guided therapy improves mortality and hospitalization rates in chronic heart failure (HF) patients.
Main Methods:
- Systematic search of RCTs involving BNP-guided therapy versus usual care in chronic HF outpatients.
- Meta-analysis included 8 RCTs with 1726 patients, a mean follow-up of 16 months.
- Data analysis focused on all-cause mortality, all-cause hospitalization, and survival free of hospitalization.
Main Results:
- BNP-guided therapy significantly reduced all-cause mortality (RR 0.76, P = .003).
- A significant mortality reduction was observed in patients younger than 75 (RR 0.52, P = .005), but not in those 75 or older (RR 0.94, P = .70).
- No significant differences were found in all-cause hospitalization (RR 0.82, P = .12) or survival free of hospitalization (RR 1.07, P = .58).
Conclusions:
- BNP-guided therapy effectively reduces all-cause mortality in chronic HF patients, especially those under 75.
- Increased utilization of evidence-based HF medications may contribute to the observed survival benefit.
- BNP-guided therapy did not significantly impact all-cause hospitalization or survival free of hospitalization.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...